Abstract
Aerosol transmission has been a pathway for virus spread for many viruses. Similarly, emerging evidence regarding SARS-CoV-2, and the resulting pandemic as declared by WHO in March 2020, determined aerosol transmission for SARS-CoV-2 to be significant. As such, public health officials and professionals have sought data regarding the effect of Heating, Ventilation, and Air Conditioning (HVAC) features to control and mitigate viruses, particularly coronaviruses. A systematic review was conducted using international standards to identify and comprehensively synthesize research examining the effectiveness of ventilation for mitigating transmission of coronaviruses. The results from 32 relevant studies showed that: increased ventilation rate was associated with decreased transmission, transmission probability/risk, infection probability/risk, droplet persistence, virus concentration, and increased virus removal and virus particle removal efficiency; increased ventilation rate decreased risk at longer exposure times; some ventilation was better than no ventilation; airflow patterns affected transmission; ventilation feature (e.g., supply/exhaust, fans) placement influenced particle distribution. Some studies provided qualitative recommendations; however, few provided specific quantitative ventilation parameters suggesting a significant gap in current research. Adapting HVAC ventilation systems to mitigate virus transmission is not a one-solution-fits-all approach but instead requires consideration of factors such as ventilation rate, airflow patterns, air balancing, occupancy, and feature placement.
Practical Implications Increasing ventilation, whether through ventilation rates (ACH, m3/h, m3/min, L/min) or as determined by CO2 levels (ppm), is associated with decreased transmission, transmission probability/risk, infection probability/risk, droplet persistence, and virus concentration, and increased virus removal and efficiency of virus particle removal. As well, professionals should consider the fact that changing ventilation rate or using mixing ventilation is not always the only way to mitigate and control viruses as varying airflow patterns and the use of ventilation resulted in better outcomes than situations without ventilation. Practitioners also need to consider occupancy, ventilation feature (supply/exhaust and fans) placement, and exposure time in conjunction with both ventilation rates and airflow patterns. Some recommendations with quantified data were made, including using an air change rate of 9 h-1 for a hospital ward; waiting six air changes or 2.5 hours before allowing different individuals into an unfiltered office with ∼2 fresh air changes (FCH) and one air change for a high-efficiency MERV or HEPA filtered laboratory; and using a pressure difference between -2 and -25 Pa in negative pressure isolation spaces. Other recommendations for practice included using or increasing ventilation, introducing fresh air, using maximum supply rates, avoiding poorly ventilated spaces, assessing fan placement and potentially increasing ventilation locations, and employing ventilation testing and air balancing checks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is funded by a Canadian Institutes of Health Research (CIHR) Operating Grant: Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding Opportunity [https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=422567&lang=en]. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation. Drs. Fleck and Zhong are supported by the NSERC Discovery program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: Dr. Fleck is an unpaid advisor for Pura Air Inc. in Vancouver.
Funding: This work is funded by a Canadian Institutes of Health Research (CIHR) Operating Grant: Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding Opportunity [https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=422567&lang=en]. Dr. Hartling is supported by a Canada Research Chair in Knowledge Synthesis and Translation. Drs. Fleck and Zhong are supported by the NSERC Discovery program.
Data Availability
All data produced in the present work are contained in the manuscript
